For MANY patients with persisitent diabetic macular edema (DME)
people person person person person person person person person Full Prescribing Information View the data

SCROLL FOR IMPORTANT SAFETY INFORMATION

INDICATION
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Important Safety Information

CONTRAINDICATIONS

  •   ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.
       
  •   ILUVIEN is contraindicated in patients with glaucoma who have cup to disc ratios of greater than 0.8.
       
  •   ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product.

WARNINGS AND PRECAUTIONS

  •   lntravitreal injections, including those with ILUVIEN, have been associated with endophthalmitis, eye inflammation, increased intraocular pressure. and retinal detachments. Patients should be monitored following the intravitreal injection.
       
  •   Use of corticosteroids including ILUVIEN may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.
       
  •   Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

ADVERSE REACTIONS

  •   In controlled studies. the most common adverse reactions reported were cataract development (ILUVIEN 82%; sham 50%) and intraocular pressure elevation of :::10 mm Hg (ILUVIEN 34%; sham 10%).
       
  •   Copyright© 2019 Alimera Sciences. Inc. All rights reserved. ILUVIEN is a registered trademark of Alimera Sciences. Inc. 1-844-445-8843 US-ILV-MMM-0665 03/19